# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and raises the price...
The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting und...
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines...
- SEC Filing
Guggenheim analyst Debjit Chattopadhyay maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and raises the price tar...
Jefferies analyst Kelly Shi maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and raises the price target from $13...
Centessa Pharmaceuticals revealed promising interim Phase 1 trial results for ORX750, demonstrating significant improvements in...
ORCL: 9% | Oracle shares are trading higher following better-than-expected Q1 financial results. JMP Securities upgraded the st...